Obalon Therapeutics Inc (NASDAQ:OBLN) VP Matthew Norwood purchased 1,000 shares of the stock in a transaction on Wednesday, October 12th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $15,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Obalon Therapeutics Inc (NASDAQ:OBLN) opened at 13.92 on Thursday. The firm has a 50-day moving average of $14.76 and a 200 day moving average of $14.76. Obalon Therapeutics Inc has a one year low of $13.92 and a one year high of $15.88.

Obalon Therapeutics Company Profile

Obalon Therapeutics, Inc is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.

5 Day Chart for NASDAQ:OBLN

Receive News & Stock Ratings for Obalon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics Inc and related stocks with our FREE daily email newsletter.